CA-JUNIPER-NETWORKS
12.12.2022 15:35:36 CET | Business Wire | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that it has been selected by Deutsche Telekom (DT) as the first network technology partner for Magenta Business Networks SD-X. By leveraging the Juniper AI-driven Enterprise solution, DT’s innovative new universal managed services platform will power exceptional user experiences with simplified zero touch deployments, proactive self-driving automation, connected security and unique client-to-cloud insight.
SD-X is a cloud-based, virtualized and automated platform that will provide a rapid, simplified and cost-effective transition from MPLS to software-defined network services for thousands of European enterprises, including small-to-midsize organizations that might otherwise find the cost and complexity of owned infrastructure to be prohibitive. Juniper is providing DT with advanced technologies to create a secure, software-driven network fabric that uses AI to provide actionable insights on real-time performance coupled with automated mitigation. This approach enables SD-X to deliver optimal user, device and application experiences to its customers as they navigate digital transformation in support of agile, differentiated business capabilities. The managed services offered provide secure networking for campus and branch environments, enabling rich new service functionality and enhanced performance.
News Highlights
- Magenta Business Networks SD-X will leverage Juniper’s full AI-driven Enterprise portfolio, starting with secure SD-WAN and expanding to wired and wireless access.
- The Juniper solution provides client-to-cloud service levels with AI-driven intelligence to optimize and maintain the best user experiences. With AI-driven insight, problems are proactively discovered and addressed via recommended actions and/or self-driving network operations. This minimizes downtime while maximizing end user experiences on the SD-X network.
- Zero touch provisioning with automated workflows enable the SD-X solution services to be pre-configured and easily deployed remotely, saving time and money while minimizing installation errors. The time for new network services to be up-and-running is reduced from weeks or months to just a few days.
- Customers can easily change network policies and security settings remotely at any time using a cloud-hosted SD-X portal, with no manual intervention or site visits needed. Simultaneous updates can be made across a customer’s entire network, so consistent policies are applied between sites.
- By leveraging a microservices cloud, DT can easily update services across the entire Juniper portfolio with little to no downtime.
AI-driven Automation, Insight and Assurance Powers User Experience
The network is the digital lifeblood of today’s enterprise, requiring anywhere, anytime access between users and data. But increased levels of traffic, diversity in devices and distributed location of users can make it extremely challenging to deliver great experiences from client-to cloud. By deploying “smart” AI-driven networking technology from Juniper that can understand user behavior in real-time and automatically optimize the network to lower costs and maximize experiences, SD-X is able to deliver a differentiated and compelling managed service to its subscribers.
Supporting Quotes
“With the relentless pace and demands of modern businesses, our customers need managed services that optimize user experiences while minimizing operational costs. We have built SD-X as a gateway to accessible, progressive enterprise networking without the need for advanced in-house capabilities and technical resources. DT’s vision is made possible thanks to Juniper’s innovation with AI, automation and the cloud, which creates an agile network for our customers that is highly differentiated in the industry.”
- Sherif Rezkalla, VP Portfolio, Head of Business Networks, Deutsche Telekom
“DT has fully embraced the powerful value of intelligent networks with SD-X. This highly-scalable business model is more cost-effective than traditional approaches, while providing the agility and ease of use customers demand. In turn, these customers can use SD-X as the foundation for an experience-driven digital business for their own customers and employees. We look forward to working with DT to roll out more managed services across SD-X to deliver a game-changing networking experience.”
- Manoj Leelanivas, Chief Operating Officer, Juniper Networks
Additional Resources
Case Study: Deutsche Telekom transforms network service delivery
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
